Allergan: BELKYRA Receives Positive Opinion From Swedish Medical Products Agency

(RTTNews) - Allergan plc (AGN) announced it has received a Positive Opinion from the Swedish Medical Products Agency for BELKYRA for the treatment of moderate to severe convexity or fullness associated with submental fat, often called double chin, in adults when the presence of submental fat has a psychological impact for the patient.

BELKYRA is being evaluated through the decentralised procedure, with the Swedish MPA acting as the Reference Member State for 20 other countries in the European Union, as well as Iceland and Norway. As a next step, Allergan will work to secure the national Marketing Authorisations in the Concerned Member States. BELKYRA is already licensed in Canada, as well as in the U.S. as KYBELLA.